Erratum: Botulinum toxin type A in post-stroke lower limb spasticity: A multicenter, double-blind, placebo-controlled trial (Journal of Neurology DOI 10.1007/s00415-010-5526-3);Botulinum toxin type A in post-stroke lower limb spasticity: A multicenter, double-blind, placebo-controlled trial

Journal of Neurology

Volumn 257, Issue 8, 2010, Pages 1330-1337

  Kaji, Ryuji ^a   Osako, Yuka ^b   Suyama, Kazuaki ^b   Maeda, Toshio ^b   Uechi, Yasuyuki ^b   Iwasaki, Masaru ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Development and Medical Affairs Division   (Japan)

Author keywords

Botulinum toxin; Clinical trials randomized controlled; Lower limb; Modified Ashworth Scale; Spasticity

Indexed keywords

BOTULINUM TOXIN A; GSK 1358820; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANKLE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERYTHEMA; FEMALE; GAIT; HUMAN; INJECTION SITE PAIN; JAPANESE; LIMB DISEASE; LOWER LIMB SPASTICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE TONE; MYALGIA; PAIN; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SPASTICITY; SPRAIN; STROKE; STROKE PATIENT; UNSPECIFIED SIDE EFFECT;

EID: 77955924018     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5607-3     Document Type: Erratum

References (28)

1. Lance JW (1980) Symposium synopsis. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Year Book Medical Publishers, Chicago, pp 485-494
2. AB Ward 2002 A summary of spasticity management-a treatment algorithm Eur J Neurol 9 Suppl 1 48 52 10.1046/j.1468-1331.2002.0090s1048.x 11918650
3. MA Grazko KB Polo B Jabbari 1995 Botulinum toxin A for spasticity, muscle spasms and rigidity Neurology 45 712 717 1:STN:280:DyaK2M3ktVymtw%3D%3D 7723960
4. P Burbaud L Wiart JL Dubos, et al. 1996 A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients J Neurol Neurosurg Psychiatry 61 265 269 10.1136/jnnp.61.3.265 1:STN:280:DyaK28zovVWqtA%3D%3D 8795597
5. F Reiter M Danni G Lagalla G Ceravolo L Provinciali 1998 Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke Arch Phys Med Rehabil 79 532 535 10.1016/S0003-9993(98)90068-5 1:STN:280:DyaK1c3lsFygsQ%3D%3D 9596394 (Pubitemid 28222165)
6. J Dunne 2002 Botulinum toxin type A (BOTOX) in the treatment of lower limb spasticity during stroke rehabilitation Intern Med J 33 Suppl A41
7. F Mancini G Sandrini A Moglia G Nappi C Pacchetti 2005 A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot Neurol Sci 26 26 31 10.1007/s10072-005-0378-9 1:STN:280:DC%2BD2M3kt1KitA%3D%3D 15877184 (Pubitemid 40723938)
8. S Farina C Migliorini M Gandolfi, et al. 2008 Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke Funct Neurol 23 2 87 91 18671909
9. RL Rosales AS Chua-Yap 2008 Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity J Neural Transm 115 617 623 10.1007/s00702-007-0869-3 1:CAS:528: DC%2BD1cXksFygs7s%3D 18322637
10. D Verplancke S Snape CF Salisbury PW Jones AB Ward 2005 A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury Clin Rehabil 19 117 125 10.1191/0269215505cr827oa 1:STN:280:DC%2BD2M7ivVOntw%3D%3D 15759526 (Pubitemid 40309182)
11. RW Bohannon MB Smith 1987 Interrater reliability of a Modified Ashworth Scale of muscle spasticity Phys Ther 67 206 207 1:STN:280:DyaL2s7hvVCksg%3D%3D 3809245
12. ® Botulinum Toxin Product Information Version 1.0 (2008) Allergan Australia Pty. Limited
13. RN Boyd HK Graham 1999 Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy Eur J Neurol 6 suppl 4 S23 S35 10.1111/j.1468-1331.1999.tb00031.x
14. LA Koman JF Mooney III BP Smith A Goodman 1993 Management of cerebral palsy with botulinum toxin A: preliminary investigation J Pediatr Orthop 13 489 495 1:STN:280:DyaK3szotFSltw%3D%3D 8370782
15. IS Corry AP Cosgrove CM Duffy S McNeill N Eames TC Taylor HK Graham 1998 Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial J Paediatr Orthop 18 304 311 10.1097/00004694-199805000-00006 1:STN:280:DyaK1c3mtFWrsg%3D%3D (Pubitemid 28212938)
16. JNS Matthews DG Altman MJ Campbell P Roytson 1990 Analysis of serial measurements in medical research BMJ 300 230 235 10.1136/bmj.300.6719.230 1:STN:280:DyaK3c7otFKqsg%3D%3D 2106931
17. C Liu A Li Wan Po LD Blumhardt 1998 "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis J Neurol Neurosurg Psychiatry 64 726 729 10.1136/jnnp.64.6.726 1:STN:280:DyaK1czgvFGitg%3D%3D 9647299
18. B Pham A Cranney M Boers AC Verhoeven G Wells P Tugwell 1999 Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials J Rheumatol 26 3 712 716 1:STN:280:DyaK1M7ovVGktg%3D%3D 10090188
19. SJ Smith E Ellis S White AP Moore 2000 A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury Clin Rehabil 14 5 13 10.1191/026921500666642221 1:STN:280:DC%2BD3c7ltFSntQ%3D%3D 10688339
20. CC Turkel B Bowen J Liu MF Brin 2006 Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity Arch Phys Med Rehabil 87 786 792 10.1016/j.apmr.2006.02.015 16731213 (Pubitemid 43767710)
21. TJ Anderson J Rivest R Stell, et al. 1992 Botulinum toxin treatment of spasmodic torticollis J R Soc Med 85 524 529 1:STN:280:DyaK3s%2FlvFWgsg%3D%3D 1433117
22. MF Brin A Blitzer 1993 Botulinum toxin: dangerous terminology errors J R Soc Med 86 493 494 1:STN:280:DyaK2czlvVyktA%3D%3D 8078064
23. CD Marsden 1993 Botulinum toxin: dangerous terminology errors-reply J R Soc Med 86 494
24. MA Chapman R Barron DC Tanis CE Gill PD Charles 2007 Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia Clin Ther 29 1325 1337 10.1016/j.clinthera.2007.07.020 1:CAS:528:DC%2BD2sXhtVemurvF 17825685 (Pubitemid 47348118)
25. R Wenzel D Jones JA Borrego 2007 Comparing two botulinum toxin type A formulations using manufacturers' product summaries J Clin Pharm Ther 32 387 402 10.1111/j.1365-2710.2007.00835.x 1:CAS:528:DC%2BD2sXpsFKntrc%3D 17635341 (Pubitemid 47063164)
26. L Harper 2009 Botulinum toxin A-when is a unit not a unit? J Urol 181 414 415 10.1016/j.juro.2008.09.045 19019386
27. ® Product Information (2009) Allergan, Inc
28. DM Simpson JM Gracies SA Yablon R Barbano A Brashear 2009 Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study J Neurol Neurosurg Psychiatry 80 380 385 10.1136/jnnp.2008.159657 1:STN:280:DC%2BD1M3htVaksQ%3D%3D 18977811